{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:38:57Z","timestamp":1762508337947},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Data are scarce regarding intravesical maintenance therapy (MT) with the low-dose bacillus Calmette\u2013Gu\u00e9rin (BCG) Tokyo strain. We investigated the efficacy and safety of MT with a half dose of the Tokyo strain for patients following transurethral resection of nonmuscle invasive bladder cancer (NMIBC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study retrospectively reviewed clinical data on 78 patients diagnosed with intermediate or high-risk NMIBC followed by either MT (n\u2009=\u200938) or IT alone (n\u2009=\u200940) between January 2012 and March 2018. Statistical analysis was performed to compare recurrence-free survival (RFS) and adverse effects between the two groups. BCG was instilled once weekly for 6\u00a0weeks as IT, then once weekly in 2-week for a total of 20 instillations over 3\u00a0years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Kaplan\u2013Meier analyses showed that patients undergoing MT had significantly better RFS than did those undergoing IT alone (hazard ratio (HR):0.32, 95% confidence interval (CI):0.12\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.02). The 3-year RFS was 65.0% in the IT group and 89.5% in the MT group. Multivariate analysis showed that MT was associated with a reduced risk of recurrence (HR: 0.32, 95% CI:0.11\u20130.93, <jats:italic>P<\/jats:italic>\u2009=\u20090.03). One MT patient (2.6%) exhibited progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The BCG Tokyo strain showed acceptable efficacy and safety in patients undergoing MT; thus, it is a potential treatment for preventing bladder cancer recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12894-020-00766-4","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:21:27Z","timestamp":1607534487000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of maintenance therapy using a half dose of the bacillus Calmette\u2013Gu\u00e9rin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study"],"prefix":"10.1186","volume":"20","author":[{"given":"Dai","family":"Koguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetaka","family":"Moroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Iwamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"issue":"1","key":"766_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5173\/ceju.2013.01.art5","volume":"66","author":"EM Borkowska","year":"2013","unstructured":"Borkowska EM, Jedrzejczyk A, Marks P, Catto JWF, Kaluzewski B. EORTC risk tables \u2013 their usefulness in the assessment of recurrence and progression risk in nonmuscle-invasive bladder cancer in Polish patients. Cent Eur J Urol. 2013;66(1):14\u201320.","journal-title":"Cent Eur J Urol"},{"issue":"4","key":"766_CR2","first-page":"418","volume":"66","author":"R Walczak","year":"2014","unstructured":"Walczak R, Bar K, Walczak J. The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice. Cent Eur J Urol. 2014;66(4):418\u201322.","journal-title":"Cent Eur J Urol"},{"issue":"42","key":"766_CR3","doi-asserted-by":"publisher","first-page":"e8300","DOI":"10.1097\/MD.0000000000008300","volume":"96","author":"Y Quan","year":"2017","unstructured":"Quan Y, Jeong CW, Kwak C, Kim HH, Kim HS, Ku JH. Dose, duration and strain of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: meta-analysis of randomized clinical trials. Medicine. 2017;96(42):e8300.","journal-title":"Medicine"},{"issue":"1","key":"766_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/BLC-150034","volume":"2","author":"NE Power","year":"2016","unstructured":"Power NE, Izawa J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer. 2016;2(1):27\u201336.","journal-title":"Bladder Cancer"},{"issue":"2","key":"766_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u20133.","journal-title":"J Urol"},{"key":"766_CR6","unstructured":"European Association of Urology. EAU Guidelines on non-muscle-invasive bladder cancer (TaT1). 2017. https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-on-Non-muscle-Invasive-BC_TaT1-2017. Accessed 30 May 2020."},{"issue":"10","key":"766_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","volume":"15","author":"PE Spiess","year":"2017","unstructured":"Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(10):1240\u201367.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"766_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"4","key":"766_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1159\/000464432","volume":"41","author":"C Wu","year":"2017","unstructured":"Wu C, Zhou X, Miao C, Zhang J, Tang Q, Chang X, et al. Assessing the feasibility of replacing standard-dose bacillus Calmette\u2013Gu\u00e9rin immunotherapy with other intravesical instillation therapies in bladder cancer patients: a network meta-analysis. Cell Physiol Biochem. 2017;41(4):1298\u2013312.","journal-title":"Cell Physiol Biochem"},{"issue":"49","key":"766_CR10","doi-asserted-by":"publisher","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","volume":"94","author":"S Zeng","year":"2015","unstructured":"Zeng S, Yu X, Ma C, Zhang Z, Song R, Chen X, et al. Low-dose versus standard dose of Bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine. 2015;94(49):e2176.","journal-title":"Medicine"},{"issue":"1","key":"766_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1186\/s12885-018-4988-z","volume":"18","author":"Z Wang","year":"2018","unstructured":"Wang Z, Xiao H, Wei G, Zhang N, Wei M, Chen Z, et al. Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model. BMC Cancer. 2018;18(1):1108.","journal-title":"BMC Cancer"},{"issue":"5","key":"766_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/iju.13538","volume":"25","author":"J Miyazaki","year":"2018","unstructured":"Miyazaki J, Onozawa M, Takaoka E, Yano I. Bacillus Calmette\u2013Gu\u00e9rin strain differences as the basis for immunotherapies against bladder cancer. Int J Urol. 2018;25(5):405\u201313.","journal-title":"Int J Urol"},{"issue":"4","key":"766_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","volume":"36","author":"T Cernuschi","year":"2018","unstructured":"Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine. 2018;36(4):498\u2013506.","journal-title":"Vaccine"},{"issue":"4","key":"766_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","volume":"4","author":"RS Svatek","year":"2018","unstructured":"Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP. Background and update for S1602\u00a0\"a\u00a0phase\u00a0III\u00a0randomized\u00a0trial\u00a0to\u00a0evaluate\u00a0the\u00a0influence\u00a0of\u00a0BCG\u00a0strain\u00a0differences\u00a0and T\u00a0cell\u00a0priming\u00a0with\u00a0intradermal\u00a0BCG\u00a0before\u00a0intravesical\u00a0therapy\u00a0for\u00a0BCG-na\u00efve\u00a0high-grade\u00a0non-muscle invasive bladder cancer. Eur Urol Focus. 2018;4(4):522\u20134.","journal-title":"Eur Urol Focus."},{"issue":"2","key":"766_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette\u2013Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer. 1995;75(2):552\u20139.","journal-title":"Cancer"},{"key":"766_CR16","doi-asserted-by":"crossref","unstructured":"Kanagawa Urological Research Group (KURG). A 2-week maintenance regimen of intravesical instillation of Bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial. Jpn J Clin Oncol. 2012;42(9):813\u20139.","DOI":"10.1093\/jjco\/hys097"},{"issue":"4","key":"766_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","volume":"10","author":"A Irie","year":"2003","unstructured":"Irie A, Uchida T, Yamashita H, Matsumoto K, Satoh T, Koh H, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose Bacillus Calmette\u2013Gu\u00e9rin for superficial bladder cancer recurrence. Int J Urol. 2003;10(4):183\u20139.","journal-title":"Int J Urol"},{"issue":"6","key":"766_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.urology.2007.11.080","volume":"71","author":"T Yoneyama","year":"2008","unstructured":"Yoneyama T, Ohyama C, Imai A, Ishimura H, Hagisawa S, Iwabuchi I, et al. Low-dose instillation therapy with Bacille Calmette\u2013Gu\u00e9rin Tokyo 172 strain after transurethral resection: historical cohort study. Urology. 2008;71(6):1161\u20135.","journal-title":"Urology"},{"issue":"5","key":"766_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1097\/01.ju.0000154354.06892.ba","volume":"173","author":"N Ikeda","year":"2005","unstructured":"Ikeda N, Honda I, Yano I, Koyama A, Toida I. Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect. J Urol. 2005;173(5):1507\u201312.","journal-title":"J Urol"},{"issue":"3","key":"766_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of bacillus Calmette\u2013Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol. 2017;198(3):503\u201310.","journal-title":"J Urol"},{"issue":"1","key":"766_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","volume":"190","author":"A Sengiku","year":"2013","unstructured":"Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K. A prospective comparative study of intravesical Bacillus Calmette\u2013Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol. 2013;190(1):50\u20134.","journal-title":"J Urol"},{"issue":"3","key":"766_CR22","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"JR Oddens","year":"2013","unstructured":"Oddens JR, Brausi M, Sylvester RJ, Bono A, van de Beek C, van Andel G, et al. Final results of an EORTCGU cancers group randomized study of maintenance Bacillus Calmette\u2013Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372.","journal-title":"Eur Urol"},{"issue":"2","key":"766_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"AP van der Meijden","year":"2001","unstructured":"van der Meijden AP, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R, et al. Intravesical instillation of epirubicin, Bacillus Calmette\u2013Gu\u00e9rin and Bacillus Calmette\u2013Gu\u00e9rin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Uro. 2001;166(2):476\u201381.","journal-title":"J Uro"},{"issue":"2","key":"766_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Mart\u00ednez-Pi\u00f1eiro","year":"2015","unstructured":"Mart\u00ednez-Pi\u00f1eiro L, Portillo JA, Fern\u00e1ndez JM, Zabala JA, Cadierno I, Moyano JL, et al. Maintenance Therapy with 3-monthly Bacillus Calmette\u2013Gu\u00e9rin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015;68(2):256\u201362.","journal-title":"Eur Urol"},{"key":"766_CR25","unstructured":"American Urological Association. AUA Practice Resources: BCG Shortage Notice. 2019. https:\/\/www.auanet.org\/practice-resources\/bcg-info\/bcg-shortage-notice. Accessed 20 May 2020."},{"key":"766_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001023","author":"V Sharma","year":"2020","unstructured":"Sharma V, Wymer KM, Borah BJ, Saigal CS, Litwin MS, Packiam VT, et al. Cost-effectiveness of maintenance BCG for intermediate and high risk non-muscle invasive bladder cancer. J Urol. 2020. https:\/\/doi.org\/10.1097\/JU.0000000000001023.","journal-title":"J Urol"},{"issue":"4","key":"766_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","volume":"57","author":"F Saint","year":"2001","unstructured":"Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology. 2001;57(4):617\u201321.","journal-title":"Urology"},{"issue":"1","key":"766_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-5347(01)62065-2","volume":"161","author":"TM de Reijke","year":"1999","unstructured":"de Reijke TM, Boer ECDE, Kurth KH, Schamhart DH. Urinary interleukin-2 monitoring during prolonged Bacillus Calmette\u2013 Guerin treatment: Can it predict the optimal number of instillations? J Urol. 1999;161(1):67\u201371.","journal-title":"J Urol"},{"issue":"2","key":"766_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/diseases7020044","volume":"7","author":"M Miyake","year":"2019","unstructured":"Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, et al. Clinical impact of the increase in immunosuppressive cell-related gene expression in urine sediment during intravesical Bacillus Calmette\u2013Gu\u00e9rin. Diseases. 2019;7(2):44.","journal-title":"Diseases"},{"issue":"7","key":"766_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","volume":"89","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"2002","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Flores N, Isorna S, Solsona E, Sebasti\u00e1n JL, Pertusa C, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical Bacille Calmette\u2013Gu\u00e9rin with a reduced dose of 27mg in superficial bladder cancer. BJU Int. 2002;89(7):671\u201380.","journal-title":"BJU Int"},{"issue":"1","key":"766_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette\u2013Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised Phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Assoc Urol. 2014;65(1):69\u201376.","journal-title":"Eur Assoc Urol"},{"issue":"3","key":"766_CR32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/jjco\/hys225","volume":"43","author":"S Muto","year":"2013","unstructured":"Muto S, Nakajima A, Horiuchi A, Inoue M, China T, Saito K, et al. Maintenance therapy with intravesical bacillus Calmette\u2013Gu\u00e9rin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer. Jpn J Clin Oncol. 2013;43(3):305\u201313.","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"766_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.4155\/cli.13.111","volume":"3","author":"JS Russell","year":"2013","unstructured":"Russell JS, Colevas AD. Adverse event monitoring in oncology clinical trials. Clin Invest. 2013;3(12):1157\u201365.","journal-title":"Clin Invest"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12894-020-00766-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00766-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:25:34Z","timestamp":1607534734000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00766-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["766"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00766-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board at Kitasato University Hospital (B 18-148) approved this study, including the request to waive the documentation of informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}